Compare SEED & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEED | XAIR |
|---|---|---|
| Founded | 1997 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 10.5M |
| IPO Year | N/A | N/A |
| Metric | SEED | XAIR |
|---|---|---|
| Price | $1.13 | $1.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 28.5K | ★ 22.5M |
| Earning Date | 01-30-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,823,070.00 | $5,802,000.00 |
| Revenue This Year | N/A | $127.85 |
| Revenue Next Year | N/A | $179.78 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 147.74 |
| 52 Week Low | $0.74 | $0.67 |
| 52 Week High | $2.70 | $10.40 |
| Indicator | SEED | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 36.61 | 41.96 |
| Support Level | $1.17 | $1.43 |
| Resistance Level | $1.36 | $2.26 |
| Average True Range (ATR) | 0.08 | 0.22 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 3.85 | 1.55 |
Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.